Literature DB >> 33796280

The smoking-dyslipidaemia dyad: A potent synergistic risk for atherosclerotic coronary artery disease.

Vineet Prakash1,2, Sams Jaker1, Amjad Burgan1, Adam Jacques3, David Fluck3, Pankaj Sharma4, Christopher H Fry5, Thang S Han4.   

Abstract

BACKGROUND: Smoking and dyslipidaemia are known individual risk factors of coronary artery disease (CAD). The present study examined the combined risk of smoking and dyslipidaemia on coronary atherosclerosis.
METHODS: Coronary artery calcium (CAC), measured by cardiac CT, was used to assess the extent of CAD, which was related to smoking and dyslipidaemia using logistic regression, adjusted for age, sex, hypertension, BMI and family history of ischaemic heart disease.
RESULTS: Seventy-one patients (46 men, 25 women: median age of 53.7yrs; IQR = 47.0-59.5) were recruited. The mean log10 CAC score in never-smokers without dyslipidaemia (reference group) was 0.37 (SD = 0.73), while the value in those with a history of smoking was 0.44 ± 0.48 (mean difference: 0.07, 95%CI:-0.67 to 0.81, p = 0.844), dyslipidaemia was 1.07 ± 1.08 (mean difference: 0.71, 95%CI: 0.24 to 1.17, p = 0.003), and both risk factors was 1.82 ± 0.64 (mean difference: 1.45, 95%CI:0.88 to 2.02, p < 0.001). For individuals in the reference group, the proportions with none, one and multiple vessel disease were 80.6%, 16.1% and 3.2%; for those with a history of smoking or with dyslipidaemia were 50.0%, 25.0% and 25.0%; and for those with both risk factors were 8.3%, 25.0% and 66.7%. Patients with a history of both risk factors had greater adjusted risks of having one- vessel disease - OR = 14.3 (95%CI = 2.1-98.2) or multiple vessel disease: OR = 51.8 (95%CI = 4.2-609.6).
CONCLUSIONS: Smoking and dyslipidaemia together are associated with high coronary artery calcification and CAD, independent of other major risk factors.
© The Author(s) 2021.

Entities:  

Keywords:  Atherosclerosis; coronary artery calcium score; ischaemic heart disease; myocardial infarct

Year:  2021        PMID: 33796280      PMCID: PMC7968041          DOI: 10.1177/2048004020980945

Source DB:  PubMed          Journal:  JRSM Cardiovasc Dis        ISSN: 2048-0040


  37 in total

1.  Diagnostic criteria for dyslipidemia.

Authors:  Tamio Teramoto; Jun Sasaki; Shun Ishibashi; Sadatoshi Birou; Hiroyuki Daida; Seitaro Dohi; Genshi Egusa; Takafumi Hiro; Kazuhiko Hirobe; Mami Iida; Shinji Kihara; Makoto Kinoshita; Chizuko Maruyama; Takao Ohta; Tomonori Okamura; Shizuya Yamashita; Masayuki Yokode; Koutaro Yokote
Journal:  J Atheroscler Thromb       Date:  2013-07-26       Impact factor: 4.928

2.  Smoking is associated with increased hepatic lipase activity, insulin resistance, dyslipidaemia and early atherosclerosis in Type 2 diabetes.

Authors:  C Kong; L Nimmo; T Elatrozy; V Anyaoku; C Hughes; S Robinson; W Richmond; R S Elkeles
Journal:  Atherosclerosis       Date:  2001-06       Impact factor: 5.162

3.  Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus.

Authors:  T Heitzer; K Krohn; S Albers; T Meinertz
Journal:  Diabetologia       Date:  2000-11       Impact factor: 10.122

Review 4.  Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis.

Authors:  Ulrich Förstermann; Ning Xia; Huige Li
Journal:  Circ Res       Date:  2017-02-17       Impact factor: 17.367

5.  Coronary CT angiography findings based on smoking status: Do ex-smokers and never-smokers share a low probability of developing coronary atherosclerosis?

Authors:  Minkyung Yi; Eun Ju Chun; Min Su Lee; Jaebong Lee; Sang Il Choi
Journal:  Int J Cardiovasc Imaging       Date:  2015-08-11       Impact factor: 2.357

6.  Stable compounds of cigarette smoke induce endothelial superoxide anion production via NADPH oxidase activation.

Authors:  Edgar A Jaimes; Eugene G DeMaster; Run-Xia Tian; Leopoldo Raij
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-04-01       Impact factor: 8.311

7.  Resveratrol induces mitochondrial biogenesis in endothelial cells.

Authors:  Anna Csiszar; Nazar Labinskyy; John T Pinto; Praveen Ballabh; Hanrui Zhang; Gyorgy Losonczy; Kevin Pearson; Rafael de Cabo; Pal Pacher; Cuihua Zhang; Zoltan Ungvari
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-05-08       Impact factor: 4.733

Review 8.  Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis.

Authors:  Kazuyuki Yahagi; Frank D Kolodgie; Fumiyuki Otsuka; Aloke V Finn; Harry R Davis; Michael Joner; Renu Virmani
Journal:  Nat Rev Cardiol       Date:  2015-10-27       Impact factor: 32.419

9.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Authors:  François Mach; Colin Baigent; Alberico L Catapano; Konstantinos C Koskinas; Manuela Casula; Lina Badimon; M John Chapman; Guy G De Backer; Victoria Delgado; Brian A Ference; Ian M Graham; Alison Halliday; Ulf Landmesser; Borislava Mihaylova; Terje R Pedersen; Gabriele Riccardi; Dimitrios J Richter; Marc S Sabatine; Marja-Riitta Taskinen; Lale Tokgozoglu; Olov Wiklund
Journal:  Eur Heart J       Date:  2020-01-01       Impact factor: 29.983

10.  Associations of body fat and skeletal muscle with hypertension.

Authors:  Thang S Han; Yasmin Y Al-Gindan; Lindsay Govan; Catherine R Hankey; Michael E J Lean
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-12-07       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.